Jewish Healthcare Foundation Releases Report on Self-Directed Patient Safety Technology
PITTSBURGH, May 28, 2025--(BUSINESS WIRE)--The technology exists for patients and families to prevent a medication error, understand what symptoms present a potentially serious condition, avoid an emergency room or hospital visit, schedule an appointment with a local specialist of high quality—all from their phone or wearable device. In a new report released today by the Jewish Healthcare Foundation (JHF), the opportunities are clear for individuals and families to play a more active role in protecting their health through emerging technologies and digital tools.
The report, Self-Directed Patient Safety: Mapping the Emerging Landscape of Consumer-Facing Innovation, developed in partnership with TEConomy Partners, LLC, comes at a critical time: medical errors remain the third leading cause of death in the United States, healthcare spending continues to rise faster than the economy, and chronic illness affects six in ten Americans. Amid these unsustainable trends, JHF's new report identifies self-directed patient safety—the empowerment of patients to prevent harm and manage care through direct-to-consumer technologies—as a promising strategy for improving outcomes while reducing costs.
"This is a generational opportunity to rethink how we approach patient safety," said Karen Wolk Feinstein, PhD, President and CEO of the Jewish Healthcare Foundation and Pittsburgh Regional Health Initiative. "By putting modern tools directly in patients' hands—like AI-powered symptom checkers, smart medication dispensers, and remote monitoring devices—we can shift from a reactive system to one focused on prevention, engagement, and shared responsibility."
She continues, "Over a decade ago, our Foundation identified four interventions that would dramatically reduce hospitalizations: managing chronic conditions in the community, greater medication scrutiny, addressing behavioral health issues as early as possible, and engaging patients in advancing their health. The first three have gotten more attention; patient engagement remains a promising but underdeveloped opportunity."
The report explores five key areas where preventable harm often occurs—medication errors, patient care errors, diagnostic errors, infection errors, and surgical errors—and showcases timely innovations across these domains. It also outlines the market forces, regulatory barriers, and investment trends shaping the future of self-directed safety.
Key findings include:
Growing innovation and venture capital activity in consumer health tech, particularly in AI-driven health IT and digital platforms.
Notable solutions are being developed to support high-risk groups such as aging adults, new parents, individuals with chronic diseases, and rare disease patients.
Significant regulatory and economic challenges slowing adoption of direct-to-consumer safety tools—yet also opportunities for leadership in regions like Pittsburgh, which combine world-class health care with technology innovation.
The report's release supports JHF's broader mission to advance patient safety and innovation in health care. It aligns closely with recent priorities from the CMS Innovation Center, including empowering people to achieve health goals, encouraging evidence-based prevention, and leveraging technology to improve care delivery.
"As the healthcare system faces unprecedented financial and human pressures, self-directed safety is a scalable, patient-centered solution," added Dr. Feinstein. "We hope this report sparks new partnerships, policies, and products that empower people to protect themselves and their loved ones."
The full report is available at jhf.org.
Available for Interviews: Karen Wolk Feinstein, PhD, President and CEO, Jewish Healthcare Foundation
About the Jewish Healthcare Foundation
The Jewish Healthcare Foundation (JHF) and its three operating arms — the Pittsburgh Regional Health Initiative (PRHI), Health Careers Futures (HCF), and the Women's Health Activist Movement Global (WHAMglobal) — offer a unique brand of activist philanthropy to advance healthcare innovation, advocacy, collaboration, and education in the interest of better health. For more information, visit jhf.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528055482/en/
Contacts
Scotland Huber, 412-594-2553huber@jhf.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Introducing Latent-X, a Frontier Generative AI Model for Protein Binder Design Accessible via No-Code Platform for Push-Button Protein Design
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Today, Latent Labs is launching Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions. The model is available for early access on Latent's no-code AI protein design platform, where users can upload protein targets and generate cyclic peptides and mini-binders directly in the browser. Through the platform, users can generate, explore, and score binder designs, selecting top-ranked structures for further lab testing. The platform includes a free tier for both commercial and non-commercial users. Sign up is available at Latent Labs is a frontier AI lab working to transform the expensive, labor intensive, and high failure rate processes of drug discovery into automated drug design. Traditional drug discovery requires screening millions of random molecules—a process where hit rates are typically well below 1% and each experiment takes months and costs thousands of dollars. With Latent-X, drug designers can generate high-confidence binders with the push of a button, achieving what would typically require testing millions of candidates by testing as little as 30 candidates per target. AI models have recently enabled solutions to previously insurmountable technical challenges in biology. With generative models, frontier AI can go beyond predicting structures to creating new sequences and structures of candidate drugs. "We envision a future where effective therapeutics can be designed entirely in a computer, much like how space missions or semiconductors are designed today," said Simon Kohl, CEO and founder of Latent Labs. "Our platform empowers scientists with lab-validated protein binder design at their fingertips, whether they're experts or new to AI-powered drug design, and without needing AI infrastructure. This is the first step on our mission toward making biology programmable in order to make drug design instantaneous." Latent-X generates functional, high affinity de novo binders with breakthrough laboratory performance. In extensive wet lab experiments across 7 therapeutic targets, Latent-X achieved 91-100% hit rates for macrocycles and 10-64% hit rates for mini-binders. The model delivered picomolar binding affinities for mini-binders and single-digit micromolar affinities for macrocycles, with generated binders showing strong target specificity. In head-to-head experimental comparisons, Latent-X exceeded the prior state-of-the-art, outperforming existing generative tools in both in silico evaluations and laboratory validation. Macrocycles are a sought after drug modality for their potential oral deliverability, with their compactness promising tissue permeability while retaining specificity. Mini-binders are a versatile new binder modality that offers high specificity in a flexible format. Full results are available in our technical report: The Latent Labs Platform allows users to access the state of the art in protein binder design in an intuitive platform for target upload, hotspot selection, binder design, and computational ranking. The platform features structure visualization, predicted structure overlays, and computational metric rankings allowing to replicate the AI workflows used to generate our successfully lab-validated binders. Latent-X is a general purpose frontier model that creates binders from scratch for unseen or previously untargeted proteins, solving the geometric puzzle of binding at the all-atom level. The model generates designs over 10x faster than previous methods and co-samples sequence and structure simultaneously, allowing for computational experimentation within seconds. Latent-X generalizes beyond nature's repertoire by generating all-atom binder structures that obey atomic-level biochemical rules, opening doors to other therapeutic modalities that depend on target-specific binding—nanobodies and antibodies being prime examples. The company is now open to partnerships to bring these expanded capabilities to new drug applications. Only five months ago Latent Labs announced its $50M funding round co-lead by Radical Ventures and Sofinnova Partners, with participation by Google's Chief Scientist Jeff Dean, Anthropic's CEO Dario Amodei and Eleven Labs' CEO Mati Staniszewski. The team consists of former AlphaFold 2 co-developers, ex-DeepMind team leads, and brings rich experience from Microsoft, Apple, Stability AI, Exscientia, Mammoth Bio, Altos Labs and Zymergen.
Business Wire
19 minutes ago
- Business Wire
E3 Lithium Announces Filing of NI 43-101 Technical Report for Updated Resource Estimate in the Garrington District
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), 'E3 Lithium' or the 'Company,' a leader in Canadian lithium, is pleased to announce that it has filed a National Instrument 43-101 – Standards of Disclosure for Mineral Projects independent technical report for its Garrington District project in central Alberta. The Garrington Report titled "NI 43-101 Technical Report for the Garrington District Lithium Resource Estimate" (the 'Garrington Report') is dated July 18, 2025, has an effective date of June 25, 2025, and the mineral resource estimate was previously disclosed by E3 Lithium in its June 25, 2025, press release titled " E3 Lithium Outlines an Inaugural Measured and Indicated Mineral Resource Estimate of 5.0 Mt LCE for the Garrington District '. There are no material changes in the Garrington Report from the results disclosed in the Company's June 25, 2025, press release. The Garrington Report is available on the Company's website ( and SEDAR+ ( Qualified Persons The disclosure in this news release of scientific and technical information pertaining to the Garrington Report has been reviewed and approved by Meghan Klein, Head of Reservoir Engineering, Americas of Sproule ERCE, and Alexey Romanov, PhD., Principal Geoscientist of Sproule ERCE. Both Ms. Klein, and Mr. Romanov are 'Qualified Person's' as defined under NI 43-101– Standards of Disclosure for Mineral Projects. Equity Awards Grant As part of the Company's 2025 compensation plan outlined March 7, 2025, the Board of Directors of the Company approved, effective June 27, 2025, the grant to Rob Knowles, VP Investor Relations, of 40,000 incentive stock options (the 'Options') exercisable to acquire up to 40,000 common shares of the Company. The options are exercisable at price of $0.81 per share for a period of three years from the date of grant under its omnibus equity incentive plan, with one half of the Options vesting on each of the first and second anniversaries of the date of grant. ON BEHALF OF THE BOARD OF DIRECTORS Chris Doornbos, President & CEO E3 Lithium Ltd. About E3 Lithium E3 Lithium is a development company with a total of 21.2 million tonnes of lithium carbonate equivalent (LCE) Measured and Indicated 1 as well as 0.3 Mt LCE Inferred mineral resources 2 in Alberta and 2.5 Mt LCE Inferred mineral resources 3 in Saskatchewan. The Clearwater Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV8% of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV8% of USD 3.7 Billion with a 24.6% IRR 1. 1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024, is available on the E3 Lithium website ( and SEDAR+ ( 2: The mineral resource NI 43-101 Technical Report for the Garrington District Lithium Resource Estimate, effective June 25, 2025, identified 5.0 Mt LCE (measured and indicated) and 0.3 Mt LCE (inferred) and is available on the E3 Lithium website ( and SEDAR+ ( 3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium website ( and SEDAR+ ( Kevin Carroll, P. Eng., Chief Development Officer of E3 Lithium and a Qualified Person under National Instrument 43-101, has reviewed and approved the technical information contained on this news release. Forward-Looking and Cautionary Statements This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions or forward-looking information within the meaning of applicable securities laws. Forward-looking statements are frequently identified by such words as 'believe', 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend', 'project', 'potential', 'possible', 'could' and similar words referring to future events and results. Forward-looking statements are based on the current opinions, expectations, estimates and assumptions of management in light of its experience, perception of historical trends, and results of the Garrington Report, but such statements are not guarantees of future performance. In particular, this news release contains forward-looking information relating to: the mineral resource estimate at the Garrington District; the potential for future development and inventory expansion of the Clearwater Project and value creation; and the anticipated benefits of the foregoing. In preparing the forward-looking information in this news release, the Company has applied several material assumptions, including, but not limited to, that activities relating to the Garrington District and the Company's other projects will not be adversely disrupted or impeded by regulatory, political, community, economic, environmental and/or healthy and safety risks; that the current price and demand for lithium will be sustained or will improve; that general business and economic conditions will not change in a materially adverse manner and that all necessary governmental approvals for the planned activities on the Garrington District will be obtained in a timely manner and on acceptable terms; the continuity of the price of lithium; that the results of the mineral resource estimate will be delivered in a timely manner consistent with the Company's projected timelines; and that the results will be in line with management's expectations. All forward-looking information (including future-orientated financial information) is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company's brine, risks related to the availability of financing on commercially reasonable terms and the expected use of proceeds; operations and contractual obligations; changes in estimated mineral reserves or mineral resources; future prices of lithium and other metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; the Company's lack of operating revenues; currency fluctuations; risks related to dependence on key personnel; estimates used in financial statements proving to be incorrect; risks related to the results of the testing program not being in delivered in a timely manner and/or not being in line with management's expectations; competitive risks and the availability of financing, as described in more detail in our recent securities filings available under the Company's profile on SEDAR+ ( Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
UPI
19 minutes ago
- UPI
DOJ drops challenge to Tennessee's gender care ban for minors
Participants walk up Market Street in the 55th annual San Francisco Pride Parade in San Francisco on Sunday, June 29, 2025. On Monday, the Justice Department dropped a lawsuit challenging Tennessee's ban on minors receiving gender-affirming medical care. File Photo by Terry Schmitt/UPI | License Photo July 22 (UPI) -- The Justice Department has dismissed a Biden-era lawsuit challenging Tennessee's law banning gender-affirming care for minors, as the Trump administration continues to attack the rights and medical care of transgender Americans. Attorney General Pam Bondi announced that her department's Civil Rights Division dismissed the lawsuit in a statement Monday that said the Justice Department "does not believe challenging Tennessee's law serves the public interest." Gender-affirming care includes a range of therapies, including psychological, behavioral and medical interventions, with surgeries for minors being exceedingly rare. According to a recent Harvard study, cisgender minors and adults were far more likely to undergo analogous gender-affirming surgeries than their transgender counterparts. Every major American medical association supports gender-affirming care for both adults and minors, including the American Academy of Pediatrics and the American Medical Association, the largest national medical association. Despite the support of the medical community and evidence of its efficacy, gender-affirming care and this marginalized community continue to be targeted by conservatives and Republicans with legislation. Tennessee enacted Senate Bill 1 in March 2023 to prohibit healthcare professionals from prescribing puberty blockers or hormones to minors to treat gender dysphoria, which attracted a lawsuit from the Justice Department under President Joe Biden, arguing the law violated the 14th Amendment's Equal Protection Clause, as all other minors continued to have access to the same procedures and treatments. The conservative movement targeting the healthcare of transgender minors has since gained a supporter in the White House with the re-election of President Donald Trump. Since returning to power, Trump has implemented an agenda targeting transgender Americans, including directing the federal government to recognize only two sexes determined at "conception," restricting gender-affirming care for youth and banning transgender Americans from the military. Last month, the conservative-leaning Supreme Court ruled 6-3 against the Biden administration's complaint to overturn the Tennessee law. The ruling fell along ideological lines, with the conservative justices voting for the law to stand. The liberal justices dissented. "By retreating from meaningful review exactly where it matters most, the Court abandons transgender children and their families to political whims," Justice Sonia Sotomayor said in her dissent. "Tennessee's ban applies no matter what a minor's parents and doctors think, with no regard for the severity of the minor's mental health conditions or the extent to which treatment is medically necessary for an individual child." Bondi on Monday said the Supreme Court made "the right decision." Assistant Attorney General Harmeet Dhillon of the Justice Department's Civil Rights Division said that by dismissing the lawsuit, they "undid one of the injustices the Biden administration inflicted upon the country."
